Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02890875

Enrollment

Registered

2016-09-07

Start date

2016-08-31

Completion date

2017-03-31

Last updated

2019-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-Related Infections

Keywords

ethanol lock, parenteral nutrition

Brief summary

Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.

Interventions

OTHEREthanol lock

OTHERHeparin lock

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adult patients (ages 18-80) on PN with silicone-based central venous catheters

Exclusion criteria

* Weight ≤ 50 kg * Allergy/hypersensitivity/intolerance to ethanol or heparin * Pregnancy or breastfeeding * Patient taking metronidazole, disulfiram, or isoniazid * History of alcohol abuse * History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable state

Design outcomes

Primary

Measure	Time frame
Central line-associated bloodstream infection	12 months

Secondary

Measure	Time frame
Hospitalization	12 months
SIRS/sepsis	12 months
Catheter-related complication	12 months
New self-reported symptoms	12 months

Other

Measure	Time frame
Microorganism (blood culture, if obtained for clinical reasons)	12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026